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Background: Several studies have shown that long-term lithium use is associated with a subtle decline in estimated
glomerular filtration rate. This study compared mean estimated glomerular filtration rates (eGFR) in patients on long
term lithium, against matched controls.
Methods: Patients with bipolar affective disorder, who are on lithium (for at least a year), were compared against
controls that were matched (1:1) for age, gender and presence or absence of diabetes or hypertension. The eGFR was
calculated from creatinine values according to the ‘modification of diet in renal disease study’ (MDRD) formula and was
compared between cases and controls. A meta-analysis was performed to compare our findings with similar studies in
literature.
Results: Forty seven patients met the inclusion criteria. They were matched with 47 controls. The eGFR values of
lithium users were significantly lower (p = 0.04) compared to controls. This difference persisted between the subgroup
of lithium users without comorbidities (diabetes and hypertension) and their controls but disappeared for lithium
users with comorbidities and their controls. Nonetheless, lithium users had lower eGFR values in both subgroups. A
meta-analysis of 9 studies showed a significant lowering in the glomerular filtration rate in lithium users compared to
controls [mean difference −10.3 ml/min (95% confidence interval: -15.13 to −5.55, p < 0.0001)].
Conclusions: Lithium causes a subtle decline in glomerular filtration rate; renal function needs to be monitored in
patients on lithium treatment.Background
Lithium is an effective and inexpensive drug that has
been used for years to treat bipolar affective disorder.
It is a monovalent cation that is well absorbed by the
gastrointestinal system and completely excreted by the
kidneys. Lithium is freely filtered in the glomeruli and
90% of the filtered load is reabsorbed in the proximal tu-
bule [1]. Renal dysfunction caused by lithium is termed
lithium nephropathy, and can manifest in many ways
[2]. Firstly, lithium may induce a transient natriuresis by
antagonizing aldosterone. Secondly, it can cause nephro-
genic diabetes insipidus which is the most common
renal ill-effect of lithium. Thirdly, lithium toxicity may* Correspondence: chaturaka.rodrigo@gmail.com
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stated.predispose to acute kidney injury (due to pre-renal fai-
lure secondary to polyuria or lithium induced neurolep-
tic malignant syndrome) [3]. Lithium is also known to
cause a distal renal tubular acidification defect [2,4].
However, whether lithium plays a contributory role to
the development of chronic kidney disease (CKD) is un-
clear. Traditionally, lithium has not been considered as a
cause of CKD. Recent findings have challenged that view.
One study showed that while a majority (85%) of patients
on long term lithium had normal estimated glomerular
filtration rates (eGFR), 15% had reduced eGFRs [5]. An-
other study assessed the eGFR values of two cohorts of
patients; a group on long term lithium (up to 33 years)
and a group of lithium naïve patients treated with other
mood stabilizers. Patients on long term lithium had
significantly lower eGFR values (corrected for age and
gender) [6]. These observations raise the possibility ofl Ltd. This is an Open Access article distributed under the terms of the Creative
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tually lead to CKD. In view of this new evidence, and con-
sidering the large patient population currently on lithium,
investigating whether long term lithium use causes a re-
duction in eGFR is timely. The objectives of this study
were to compare the eGFR values of patients on long term
lithium with controls matched for age, gender and comor-
bidities (diabetes and hypertension).Methods
Study design and sample selection
This was a comparative cross sectional study carried out
by the University Medical Unit and the University Psy-
chiatry Unit of the National Hospital of Sri Lanka. All
consenting adult patients (18 years and above) who were
on lithium and followed up at the University Psychiatry
Unit as inpatients or outpatients were included in the
study, and their data was obtained from the clinical re-
cords. The latest and previous creatinine values of patients
were recorded, and eGFR values were calculated using the
MDRD (Modification of Diet in Renal Disease) formula
[7]. We also extracted data of patients with bipolar af-
fective disorder who were not on lithium. These two
groups were defined as below.
Group A: Patients with ICD-10 (International Classifica-
tion of Diseases) clinical diagnosis of bipolar affective dis-
order who had been treated with lithium for a minimum
period of one year. This group was further divided into
two subgroups depending on whether the patients had
diabetes or hypertension as a co-morbidity (subgroup A1:
lithium users without diabetes or hypertension, subgroup
A2: lithium users with diabetes, hypertension or both).
Group B: Patients with ICD-10 clinical diagnosis of
bipolar affective disorder but not treated with lithium
within the last 12 months. These patients were on treat-
ment with other mood stabilizers.Matching
Matching was done on a 1:1 basis for patients in sub-
groups A1 and A2 (group B was too small to carry out any
comparisons). Patients from the University Medical Unit,
who were admitted to wards or followed up in clinics due
to a non-renal illness or for evaluation purposes (and
therefore had a serum creatinine value recorded) were re-
cruited as controls. The clinics of the University Medical
Unit have a population of approximately 1500 patients
followed up as outpatients. The selection of a control was
done by checking each registered patient on a randomly
selected clinic date according to the matching criteria de-
tailed below.
Controls for subgroup A1: Patients without a) a psy-
chiatric condition (and not on lithium), b) diabetes or
hypertension and c) any other comorbidity known toeffect the eGFR were matched to each of the A1 patients
with respect to age and gender on a 1:1 basis.
Controls for subgroup A2: Patients without a psychiatric
condition (and not on lithium) but having either a) dia-
betes, b) hypertension or c) both were matched for each
of the group A2 patients (1:1 match) with regard to the
age, gender and the type of co morbidity. For example, for
a lithium-using 56 year old male with diabetes and hyper-
tension, a non lithium-using 56 year old male with dia-
betes and hypertension was selected as the control.
Data extraction
Data pertaining to following aspects were collected from
the recruits using a pre-tested interviewer administered
data sheet: demography, past medical history, past psy-
chiatric history, treatment history of lithium, complica-
tions of lithium therapy and serial creatinine values while
on lithium.
The following patient categories were excluded from
this study: a) patients on lithium diagnosed with renal dis-
ease or CKD due to another aetiology, b) non-consenting
patients, c) patients with acute kidney injury, d) patients
with an alternative cause for a high serum creatinine (e.g.
myositis), e) patients with poor compliance with lithium
and f) extremes of body mass index (18 < and > 30 kg/m2).
Ethical clearance for the study was granted by the
Ethics Review Committee of the National Hospital of
Sri Lanka.
Statistical analysis
eGFR values were compared between the groups using
mean differences. Significance of mean differences in
eGFR between groups was calculated with the Indepen-
dent t test. Statistical significance was set at p < 0.05.
Descriptive statistics were summarized into proportions
and averages based on the scales of measurement. SPSS
statistical software (version 15) was used for data analysis.
Linear regression was used to correlate two continuous
variables.
Meta-analysis
A recent meta-analysis has compared the eGFR values
between lithium users and controls from studies published
up to 2010 [8]. We built on that meta-analysis. We
searched EMBASE, SCOPUS and PUBMED for publica-
tions between January 2011 – October 2013 which had
the keywords “Lithium” and “glomerular filtration rate” or
“GFR” or “eGFR” in the abstract. This time period was not
covered by the previous meta-analysis. Three authors
independently carried out the search and the data was
filtered using Endnote X4 software (Thomson Reuters,
Carlsbad, CA 92011, USA). Relevant studies published
after 2010, and the data from our study were added to the
data of studies identified in the previously published
Rodrigo et al. BMC Psychiatry 2014, 14:4 Page 3 of 7
http://www.biomedcentral.com/1471-244X/14/4review and a new independent meta-analysis was carried
out using the Revman (version 5) software [9].
Results
Results of the study
Forty seven patients were recruited to group A and six
patients to group B. Of the group A patients, 24
belonged to subgroup A1 and 23 to subgroup A2. Of the
patients in subgroup A2, 11 had diabetes, six had hyper-
tension and six patients had both co-morbidities. The
characteristics of group A and its controls are given in
Table 1. Since the numbers were small in group B, they
were used for an overall comparison of eGFR only
(Table 2).
Group A had a higher number of patients with hy-
pothyroidism which is a known complication of long term
lithium therapy (seven patients among lithium users vs.
one patient in the control group). The mean duration of
diabetes and hypertension were greater among controls
than the cases. Comparing the two subgroups (A1, A2) of
lithium users, those with comorbidities (A2) were older
and had been on lithium for a longer duration (Table 1).
None of the lithium users had a recorded history of any
other lithium related renal complication such as diabetes
insipidus, acute kidney injury or renal tubular acidosis.
The patients on lithium (Group A, n = 47) had a mean
eGFR value of 79.71 ml/min/1.73 m2 (SD ± 22.6, median:
79.9, interquartile range: 70.5 – 94.3). The age and gen-
der matched controls (n =47) had a mean eGFR value of
89.31 ml/min/1.73 m2(SD ± 21.3, median: 90.6, inter-
quartile range: 77.2 – 105.7). This difference was statisti-
cally significant (t- 2.12, df – 92, p = 0.04). Serial data on
creatinine values were available for only 34 patients
among the lithium users and the mean rate of decline of
eGFR per year in that subgroup was −2.7 ml/min/
1.73 m2 (SD ± 9.8). The comparisons of mean eGFR of
the sub groups are summarized in Table 2. Notably, im-
pairment in eGFR remains statistically significant for the
comparison between subgroup A1 and their controls.
Correlation of eGFR values with duration of lithiumTable 1 Characteristics of cases and controls in the study




Mean age 42.68 ± 13.3
Mean duration of diabetes (in years) N/A
Mean duration of hypertension (in years) N/A
Range of dose of lithium (mg) 250 - 1500
Mean duration of lithium use (in years) 9.04 ± 5.9
N/A: not applicable.therapy by linear regression (controlling for age and
gender) showed a negative trend which was not statisti-
cally significant (beta = −0.07, B = −0.16, p = 0.66).
Results of the meta-analysis
The previously published review by McKnight et al. [8]
had considered six studies in their paper [10-15]. We
traced the original papers of these studies and re-entered
the data for a new meta-analysis. Our search for the
period from 2011 January to 2013 October recovered only
one study with usable data [6]. There was another suitable
study published in 2010 which had not been included in
the earlier meta-analysis [16]. These data plus the results
of our study were considered for the new meta-analysis.
For five out of six studies of the earlier meta-analysis, the
GFR values extracted by us were the same. However, in
the remaining study (by Turan et al. [15]) we noted that
the original authors had considered three groups of pa-
tients namely; lithium naïve patients, short term lithium
users (less than three years) and long term lithium users
(greater than 3 years). It seems the authors of the review
had opted to include the GFR of short term lithium users
for comparison. We felt that given the duration of lithium
use in our study and other studies included in the meta-
analysis, it was more appropriate to take the GFR values
of the long term user group. This changed the direction of
overall effect for that study compared to what was pub-
lished in the previous meta-analysis [15] (See below). The
results of our meta-analysis confirmed that lithium users
had significantly lower GFR values compared to non-using
controls; (9 studies, mean difference −10.3 ml/min, 95%
CI: -15.13 to −5.55, 471 cases, 337 controls, p < 0.0001)
(Figure 1). A summary of studies included in the meta-
analysis is given in Table 3.
Discussion
Many of the earlier comparative studies on the effect
of lithium on eGFR/GFR have only controlled for the
traditional variables of age and gender, and have not







(n-23) (n- 24) (n-23)
Mean ± SD
57.68 ± 9.3 42.66 ± 14.1 57.61 ± 8.9
3.22 ± 3.3 N/A 6.77 ± 3.0
5.42 ± 5.1 N/A 7.85 ± 4.8
250 - 1000 N/A N/A
11.5 ± 9.3 N/A N/A
Table 2 Mean estimated glomerular filtration rates (eGFR)
of different subgroups of lithium users compared to
respective control groups
Group Mean (ml/min/1.73 m2)
± SD
T statistic
Patients on lithium without
hypertension or diabetes
(Group A1, n - 24)
83.12 ± 27.4
2.07*
Controls for group A1
(n- 24)
97.01 ± 18.4
Patients on lithium with
hypertension and diabetes
(group A2, n - 23)
75.85 ± 15.1
0.97
Controls for group A2
(n – 23)
81.27 ± 21.5
Patients with bipolar affective
disorder who were not on
lithium (n – 6)
98.58 ± 32.3 Not used for
comparison
*p < 0.05.
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count in the more recently published study by Bocchetta
et al. [6] but their adjustments for these confounders
were done by means of a regression analysis. In this ana-
lysis age and gender showed a significant effect on eGFR
(as expected) in addition to duration of lithium treat-
ment. However, smoking, diabetes, dyslipidaemia and
hypertension were not shown to have a significant effect
on eGFR values. In our study, we attempted to control
for some of these confounding factors when matching
cases and controls. The controls were matched with re-
gard to age, gender and the commonest comorbidities
known to effect eGFR on the long term; diabetes and
hypertension. This design of prospectively eliminating
bias (rather than with a regression analysis) increased
the validity of results.
Some studies quoted in the meta-analysis have classi-
fied patients into stages of CKD based on the eGFR
[6,16]. However we did not classify our patients into
eGFR categories meant for chronic kidney disease as this
classification has opened up a debate about classifying
apparently “healthy” people with eGFR values above 60Figure 1 Forest plot for the comparison of glomerular filtration ratesas having CKD stage II [17]. Furthermore, albuminuria
is also now taken in to consideration in determining
CKD risk and this data was not available for many stu-
dies including ours. Therefore, we restricted ourselves to
a comparison of mean eGFR values of cases and controls
only.
Overall, it was noted that patients on lithium (either
with or without comorbidities) had lower eGFR values
compared to their respective control groups. Our study
demonstrates that long term lithium use may be an in-
dependent risk factor for a decline in eGFR even after
controlling for age and gender related changes. When
patients have comorbidities such as diabetes and hyper-
tension, chronic lithium use may add on to the burden
of declining eGFR but it is difficult to discern the effect
of lithium from the effects of these illnesses. We only
controlled the groups for the presence or absence of dia-
betes/hypertension but not for the duration or degree of
control of these comorbidities. It is noted that patients
in the control group had a longer mean duration of dia-
betes and hypertension (hence higher propensity for re-
sultant renal impairment) compared to the lithium users
with these complications. That might have prevented us
from observing a significant difference in the eGFR in
this subgroup (A2) and their controls.
One of the first studies that suggested a role of long
term lithium use precipitating end stage kidney disease
was a large population based study in Sweden. The
investigators demonstrated that lithium users had a six-
fold greater risk of needing renal replacement therapy
compared with the general population [18]. However,
the authors noted that end-stage kidney disease attri-
butable to lithium is uncommon (only 18 patients
were detected out of 3369 lithium treated patients). The
mean duration of lithium use among these patients was
23 years. In our study, none of the lithium using patients
had an eGFR value in the end stage kidney disease range,
but the mean duration of lithium use in our sample was
less than 10 years. In the previous study, the prevalence
of CKD (excluding those with end stage disease) in the
lithium treated general population was around 1.2%of lithium taking patients and controls.
Table 3 Characteristics of studies included in the meta-analysis
Study Methods Results (values are given as mean ± SD) Comments
Hullin et al. [10] Comparative study Mean duration of lithium treatment;
8.3 ± 2.8 years
GFR assessed by creatinine clearance
Lithium group; 30 patients GFR of lithium group; 61.1 ± 30.2 ml/min
Control group; age and gender
matched 30 psychiatric patients
not on lithium
GFR of controls; 81.3 ± 52.0 ml/min
Bendz et al. [11] Comparative study Mean duration of lithium treatment;
5.7 ± 2.7 years
GFR assessed by endogenous creatinine
clearance was taken for meta-analysis
lithium group; 32 patients GFR of lithium group; 90 ml/min
Control group; 32 age and
gender matched psychiatric
patients not on lithium
GFR of controls; 94 ml/min
Hetmar et al. [13] Comparative study Mean duration of lithium treatment;
10 years
GFR assessed by endogenous creatinine
clearance was taken for meta-analysis
lithium group; 32 patients GFR of lithium group; 88.8 ± 18.0 ml/min When corrected for the age difference, there
was no significant difference between the
GFR of two groups
Control group; 53 non matched
patients with affective disorders
not on lithium
GFR of controls; 101.4 ± 21.6 ml/min
Bendz et al. [12] Comparative study Mean duration of lithium treatment;
18 years
GFR assessed by endogenous creatinine
clearance
lithium group; 13 patients GFR of lithium group; 69 ± 4 ml/min
Control group; 13 age and
gender matched psychiatric
patients not on lithium
GFR of controls; 78 ± 4 ml/min
Coskunol et al. [14] Comparative study Mean duration of lithium treatment;
4.5 ± 3.9 years
This is the only study that showed the
lithium group to have a higher GFR value.
However, the numbers in control group
were few and they were not matched for
cases.
lithium group; 107 patients GFR of lithium group; 86.5 ± 21.6 ml/min GFR assessed by endogenous creatinine
clearance
Control group; 29 psychiatric
patients not on lithium and
without bipolar affective disorder
GFR of controls; 83.9 ± 20.5 ml/min
Turan et al. [15] Comparative study Mean duration of Lithium treatment
(for long term users); 6.6 ± 2.0 years
GFR assessed by endogenous creatinine
clearance
Lithium group; 20 patients (10 as
short term users and 10 as long
term users)
GFR of long term lithium group;
72.8 ± 30.9 ml/min
Considering the average duration of lithium
use in other studies of the meta-analysis,
long term lithium users were the appropri-
ate group to include in the analysis in our
opinion.
Long term users had a duration
of use more than 3 years
GFR of controls; 125.3 ± 18.1 ml/min (please also see the comments in
discussion)
Control group; 10 lithium naïve
unmatched patients with bipolar
affective disorder
Tredget et al. [16] Comparative study Mean duration of Lithium treatment;
15.6 ± 6.4 years
GFR was estimated with the modification of
diet in renal disease (MDRD) study formula
using the serum creatinine value and other
parameters
Lithium group; 61 patients eGFR of long term lithium group;
66.1 ± 15.5 ml/min
Control group; 53 non lithium
using patients with affective
disorders
eGFR of controls; 75 ± 16.7 ml/min
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Table 3 Characteristics of studies included in the meta-analysis (Continued)
Bocchetta et al. [6] Comparative study Duration of lithium treatment; range – 1 to
33 years (mean duration not given), majority
were users for more than 10 years according
to a figure quoted in article
GFR was estimated with the modification of
diet in renal disease (MDRD) study formula
using the serum creatinine value and other
parameters
Lithium group; 139 patients with
bipolar affective disorder
Mean difference of eGFR between cases and
controls were; -12 ml/min (95% CI; -17.5 to
6.5 ml/min)
Control group; non matched 70
patients with affective disorders
not on lithium, regression




Comparative study Mean duration of lithium treatment
(for long term users); 10.1 ± 7.6 years
GFR was estimated with the modification of
diet in renal disease (MDRD) study formula
using the serum creatinine value and other
parameters
lithium group; 47 patients with
bipolar affective disorder
eGFR of lithium group; 79.7 ± 22.6 ml/min
Control group; 47 people
without a psychiatric illness
matched for age, gender and
comorbidities (diabetes and
hypertension)
eGFR of controls; 89.3 ± 21.3 ml/min
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150 μmol/l).
The previously mentioned meta-analysis on lithium in-
duced complications and toxicity concluded that on aver-
age, lithium use was associated with a – 6.22 ml/min/
1.73 m2 lower GFR compared to controls [8]. This data
came from six comparative studies. Two of them have
demonstrated a significant drop in eGFR in lithium users
[12,13] while two others have reported a non-significant
decline in eGFR [10,11]. The overall effect was towards a
reduction in eGFR, but this was not statistically signifi-
cant. An important reason for this non-significant result
was the study by Turan et al. [15] which had reported a
paradoxical rise in GFR in lithium users. We interpreted
the results of this study differently as mentioned above.
This resulted in a change in the direction of effect for this
study which was in keeping with the results of other stu-
dies, and the overall effect for the six studies in the ori-
ginal meta-analysis became significant. After adding the
results of our study and the other two studies, the meta-
analysis showed a significantly lower value of eGFR/GFR
in chronic lithium users compared to non using controls.
The practice of liberal use of lithium as the drug of
choice in bipolar affective disorder without proper moni-
toring of renal function has to be revisited in the light of
these findings. However, it must be noted that the de-
cline of eGFR/GFR with lithium use is subtle (although
significant) and only a small proportion of lithium using
patients may end up in end stage kidney disease. The
exact pathology of lithium induced GFR change is still
unknown and it should not be reduced to a simplistic
view of longer duration of use causing renal impairmentwith time. Not all patients who are on long term therapy
develop end stage disease, and our study and well as that
by Tredget et al. [16] showed that duration of lithium
use only had a non-significant negative association with
eGFR. It is highly likely that other factors (individual
and environmental) may be at play and future research
should be aimed at elucidating the relationships between
potential secondary contributing factors.
Limitations
The numbers in our lithium using patient sample was
limited by the fact that we excluded patients with poor
compliance (patient reported compliance). We did not
measure the serum lithium level of our recruited pa-
tients as a single current lithium level does not reflect
compliance over many years. Unfortunately, facilities to
measure serum lithium is not regularly available to pa-
tients free of charge and therefore such measurements
had not been done for us to have an idea about patient
compliance over time. The state-run clinics like ours
provide free health care to patients, but investigations
like serum lithium level are not available all the time.
Most patients seeking health care in state-run cannot af-
ford to get serum lithium levels tested from private sec-
tor laboratories. Several patients in the lithium-using
category did not have periodic serial serum creatinine
values in clinic records. Such patients were excluded
from the analysis of the rate of decline in eGFR. Current
guidelines suggest that eGFR alone is an inadequate mea-
sure to define at risk groups for CKD, and albuminuria
also has to be taken in to account [19]. This measure was
not compared between cases and controls in our study.
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according to CKD risk categories or stages.
Conclusions
This study showed that patients on long-term lithium
had lower eGFR values that were statistically significant
compared to age and gender matched controls. When
patients with long standing diabetes and hypertension
(confounders) were excluded from the analysis, the sta-
tistical significance persisted, indicating that chronic
lithium use may in fact be the cause for the lower eGFR.
Comparison of a subgroup of lithium users with diabetes
and hypertension with respective controls showed a
non-significant decline in eGFR in lithium users. A new
meta-analysis carried out by us based on a meta-analysis
published in 2012 (of studies published up to 2010)
concluded that lithium causes a significant decline
in eGFR/GFR. Despite the decline of GFR, end stage
kidney disease associated with lithium seems to be un-
common. Nonetheless, in view of these findings, we
suggest that psychiatrists remain vigilant and monitor
the renal function of patients on long term lithium.
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